Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4956877 | 0.94 | CDK1 (0.52) | KDM4EHSD17B10MAPTNSD1KCNH2 | |
| SCHEMBL708875 | 0.89 | KDM4E (0.44) | KDM4EHSD17B10MAPTNSD1KCNH2 | |
| SCHEMBL29510791 | 0.89 | KDM4E (0.44) | KDM4EHSD17B10MAPTNSD1KCNH2 | |
| SCHEMBL710488 | 0.88 | KDM4E (0.58) | KDM4EHSD17B10MAPTNSD1KCNH2 | |
| SCHEMBL29510895 | 0.88 | KDM4E (0.58) | KDM4EHSD17B10MAPTNSD1KCNH2 | |
| SCHEMBL30073543 | 0.86 | FERMT2 (0.47) | CYP2D6CYP2C19NR4A2FERMT2ACVR1 | |
| SCHEMBL1695394 | 0.85 | CACNA2D1 (0.52) | KDM4EHSD17B10MAPTNSD1KCNH2 | |
| SCHEMBL706212 | 0.83 | CDK1 (0.52) | KDM4EHSD17B10MAPTNSD1KCNH2 | |
| SCHEMBL710054 | 0.82 | CDK1 (0.67) | KDM4EHSD17B10MAPTNSD1KCNH2 | |
| SCHEMBL4742329 | 0.80 | CDK1 (0.48) | KDM4EHSD17B10MAPTNSD1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | claimed |
| US-20020198231-A1 | Compositions and methods for the treatment of Parkinson's disease | Greenlee, Winner and Sullivan, P.C. | 2002-12-26 | — | — | US | claimed |
| US-20240228646-A9 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | AVIDITY BIOSCIENCES INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-12006499-B2 | Una amidites and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-11999955-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240132610-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240132611-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | Atrium Therapeutics, Inc. | 2024-04-25 | — | — | US | disclosed |
| US-20240124600-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11912779-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11872287-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230398231-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20130131155-A1 | Optimized In Vivo Delivery System with Endosomolytic Agents for Nucleic Acid Conjugates | DNA THERAPEUTICS (FR) | 2013-05-23 | — | — | US | disclosed |
| WO-2008103409-A2 | COMPOSITIONS OF CHLOROQUINE COUPLED TO ANTIBODIES AND TO OTHER PROTEINS WITH METHODS FOR THEIR SYNTHESIS | KOSAK KEN M | 2008-08-28 | — | — | WO | disclosed |
| US-20080051323-A1 | Chloroquine drug compositions and methods for their synthesis | KOSAK KENNETH M | 2008-02-28 | — | — | US | disclosed |
| US-20070166281-A1 | Chloroquine coupled antibodies and other proteins with methods for their synthesis | KOSAK KENNETH M | 2007-07-19 | — | — | US | disclosed |
| WO-2007040469-A2 | CHLOROQUINE COUPLED COMPOSITIONS AND METHODS FOR THEIR SYNTHESIS | KOSAK KEN M (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070060499-A1 | Chloroquine combination drugs and methods for their synthesis | KOSAK KENNETH M | 2007-03-15 | — | — | US | disclosed |
| US-20060040879-A1 | Chloroquine coupled nucleic acids and methods for their synthesis | KOSAK KENNETH M | 2006-02-23 | — | — | US | disclosed |
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | disclosed |
| US-20020198231-A1 | Compositions and methods for the treatment of Parkinson's disease | Greenlee, Winner and Sullivan, P.C. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872287-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | MTPN, MYOF, TNNC1 | KDM4E 3360/4885HSD17B10 1747/4885MAPT 246/4885 |
| US-20240124600-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MYOF, MTPN, PYGM | KDM4E 3452/4885HSD17B10 1117/4885MAPT 2790/4885 |
| US-20070166281-A1 | Chloroquine coupled antibodies and other proteins with methods for their synthesis | GPR119, CLTA, CHMP4B | KDM4E 3099/4885HSD17B10 4587/4885MAPT 1596/4885 |
| US-20070060499-A1 | Chloroquine combination drugs and methods for their synthesis | CHMP4B, CTSA, CLTA | KDM4E 2153/4885HSD17B10 4662/4885MAPT 1343/4885 |
| US-20130131155-A1 | Optimized In Vivo Delivery System with Endosomolytic Agents for Nucleic Acid Conjugates | EEA1, RNASE1, ASGR1 | KDM4E 4129/4885HSD17B10 4585/4885MAPT 3832/4885 |
| US-20080051323-A1 | Chloroquine drug compositions and methods for their synthesis | CHMP4B, CTSA, CLTA | KDM4E 2091/4885HSD17B10 4621/4885MAPT 1241/4885 |
| US-11912779-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | MYOF, MTPN, PYGM | KDM4E 3452/4885HSD17B10 1117/4885MAPT 2790/4885 |
| US-20230398231-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | TNNC1, PYGM, MYOF | KDM4E 3409/4885HSD17B10 2547/4885MAPT 1079/4885 |
| US-20060040879-A1 | Chloroquine coupled nucleic acids and methods for their synthesis | TLR9, TLR3, EXOSC5 | KDM4E 3418/4885HSD17B10 4564/4885MAPT 2288/4885 |
| US-20240132611-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | TFRC, FOLR1, CD47 | KDM4E 3085/4885HSD17B10 4395/4885MAPT 2515/4885 |
| US-20240132610-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MYOF, MTPN, PYGM | KDM4E 3452/4885HSD17B10 1117/4885MAPT 2790/4885 |
| US-12006499-B2 | Una amidites and uses thereof | NCL, PNP, NASP | KDM4E 4566/4885HSD17B10 3005/4885MAPT 506/4885 |
| US-20240228646-A9 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | TFRC, FOLR1, CD47 | KDM4E 3085/4885HSD17B10 4395/4885MAPT 2515/4885 |
| US-11999955-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | MTPN, MYOF, CPT1B | KDM4E 3478/4885HSD17B10 1412/4885MAPT 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.